UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Immune Checkpoint Molecule BTLA Attenuates Experimental Glomerulonephritis by Directly Inhibiting T Effector Cells and Inducing Treg Differentiation: FR-PO600

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.487-487

2022

Link zum Volltext

Verfügbarkeit prüfen

A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature

Rheumatology (Oxford, England), 2023-10, Vol.62 (10), p.3459-3468

2023

Link zum Volltext

Verfügbarkeit prüfen

Stimulation of Immune Checkpoint Molecule B and T-Lymphocyte Attenuator Alleviates Experimental Crescentic Glomerulonephritis

Journal of the American Society of Nephrology, 2023-08, Vol.34 (8), p.1366-1380

2023

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

International journal of molecular sciences, 2023-10, Vol.24 (20), p.15336

2023

Link zum Volltext

Verfügbarkeit prüfen

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study

International journal of molecular sciences, 2022-07, Vol.23 (13), p.7293

2022

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine

Cancers, 2024-07, Vol.16 (14), p.2612

2024

Link zum Volltext

Verfügbarkeit prüfen

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16750-e16750

2020

Link zum Volltext

Verfügbarkeit prüfen

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Cancers, 2022-05, Vol.14 (11), p.2685

2022

Link zum Volltext

Verfügbarkeit prüfen

GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells

Journal of cellular and molecular medicine, 2023-07, Vol.27 (14), p.2082-2092

2023

Link zum Volltext

Verfügbarkeit prüfen

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

Journal of cancer research and clinical oncology, 2023-09, Vol.149 (12), p.10831-10840

2023

Link zum Volltext

Verfügbarkeit prüfen

A new digital measurement system for assessing the lip in patients with cleft lip and palate (CLP)

Journal of oral biology and craniofacial research (Amsterdam), 2023-11, Vol.13 (6), p.801-806

2023

Link zum Volltext

Verfügbarkeit prüfen

An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results

Dermato, 2023-03, Vol.3 (1), p.85-96

2023

Link zum Volltext

Verfügbarkeit prüfen

The Physiological Incubation Biosimulator (PIBS): An Improved Ex Vivo Experimental Setup for the Mechanical Stability of Biological Sealants in Surgical Procedures

Surgical innovation, 2017-06, Vol.24 (3), p.214-222

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immune Checkpoint Molecule BTLA Attenuates Experimental Glomerulonephritis by Directly Inhibiting T Effector Cells and Inducing Treg Differentiation: FR-PO600

A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature

Stimulation of Immune Checkpoint Molecule B and T-Lymphocyte Attenuator Alleviates Experimental Crescentic Glomerulonephritis

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

A new digital measurement system for assessing the lip in patients with cleft lip and palate (CLP)

An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results

Protective Effects of Therapeutic Neutrophil Depletion and Myeloperoxidase Inhibition on Left Ventricular Function and Remodeling in Myocardial Infarction

The Physiological Incubation Biosimulator (PIBS): An Improved Ex Vivo Experimental Setup for the Mechanical Stability of Biological Sealants in Surgical Procedures

Suchergebnisse filtern